GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Price-to-Tangible-Book

Cognition Therapeutics (Cognition Therapeutics) Price-to-Tangible-Book : 2.69 (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Price-to-Tangible-Book?

As of today (2024-05-11), Cognition Therapeutics's share price is $1.94. Cognition Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.72. Hence, Cognition Therapeutics's Price to Tangible Book Ratio of today is 2.69.

The historical rank and industry rank for Cognition Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

CGTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.09   Med: 1.51   Max: 2.74
Current: 2.69

During the past 5 years, Cognition Therapeutics's highest Price to Tangible Book Ratio was 2.74. The lowest was 1.09. And the median was 1.51.

CGTX's Price-to-Tangible-Book is ranked better than
50.7% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs CGTX: 2.69

A closely related ratio is called PB Ratio. As of today, Cognition Therapeutics's share price is $1.94. Cognition Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.72. Hence, Cognition Therapeutics's P/B Ratio of today is 2.69.


Cognition Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Cognition Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Price-to-Tangible-Book Chart

Cognition Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 2.74 1.51 2.43

Cognition Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.61 1.51 2.43 2.52

Competitive Comparison of Cognition Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Cognition Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognition Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's Price-to-Tangible-Book falls into.



Cognition Therapeutics Price-to-Tangible-Book Calculation

Cognition Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=1.94/0.722
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Cognition Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognition Therapeutics (Cognition Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
John Brendan Doyle officer: Chief Financial Officer C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi director, officer: CEO & President C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano officer: Chief Medical Officer C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone director C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace director C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107

Cognition Therapeutics (Cognition Therapeutics) Headlines

From GuruFocus